Interleukin 1β Blockade Reduces Intestinal Inflammation in a Murine Model of Tumor Necrosis Factor–Independent Ulcerative Colitis

BACKGROUND & AIMS: Inflammatory bowel diseases are multifactorial diseases commonly treated with either immunomodulatory drugs or anti–tumor necrosis factor (TNF). Currently, failure to respond to anti-TNF therapy (assessed no earlier than 8–12 weeks after starting treatment) occurs in 20%–40% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liso, Marina, Verna, Giulio, Cavalcanti, Elisabetta, De Santis, Stefania, Armentano, Raffaele, Tafaro, Angela, Lippolis, Antonio, Campiglia, Pietro, Gasbarrini, Antonio, Mastronardi, Mauro, Pizarro, Theresa Torres, Cominelli, Fabio, Lopetuso, Loris Riccardo, Chieppa, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120241/
https://www.ncbi.nlm.nih.gov/pubmed/35314399
http://dx.doi.org/10.1016/j.jcmgh.2022.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120241/
https://www.ncbi.nlm.nih.gov/pubmed/35314399
http://dx.doi.org/10.1016/j.jcmgh.2022.03.003

Ejemplares similares